secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verve Therapeutics, Inc. (—)
CIK:        0001840574
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001193125-24-171310
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Verve Therapeutics appoints Jodie Morrison and Vertex exec Nia Tatsis to board
------------------------------------------------------------------------------

- Board expanded to nine members; Morrison (Class I, term to 2025) and Tatsis (Class III, term to 2027) elected June 26, 2024.
- Morrison is independent; Tatsis is an executive officer of Vertex, Verve's collaborator under a 2022 strategic deal.
- Each new director received an option for 267,541 shares at $5.02 per share, vesting over three years.
- Tatsis's appointment deepens ties with Vertex, which paid Verve $25M upfront and up to $406M in milestones and royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/0001193125-24-171310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/d821295d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-171310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer